Investor Presentation Q1 2022

8 Investor presentation First three months of 2022 New GLP-1 prescriptions in the US have accelerated in the first quarter of 2022 US GLP-1 weekly NBRX prescriptions Weekly NBRX scripts ('000) 40 TRX share 60% 30 20 20 10 10 0 Apr 2020 50% 48,0% 40% 30% 20% 10% Novo Nordisk® US GLP-1 TRX market share Class growth +30% Total GLP-1 scripts ('000) 3.500 54,2% 3.000 2.500 43,4% 2.000 37,0% 1.500 1.000 9,5% 500 7,8% 0 Apr 2022 0% Apr 2022 Apr 2020 dulaglutide NN GLP-1 - VictozaⓇ OzempicⓇ Rybelsus Total monthly GLP-1 scripts Source: IQVIA Xponent, Weekly (ending 8 April 2022) Each data points represents a rolling four-week average. Total GLP-1 scripts constitute all prescriptions of GLP-1 medications in the market and have the full month of March as latest available data point NBRX: New-to-brand prescriptions; TRX: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions Note: Class growth calculated as Q1 2022 vs Q1 2021

View entire presentation